Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin

Lista, F.; Redondo, C.; Meilán, E.; García-Tello, A.; Fata, F. Ramón de; Angulo, Javier

doi:10.1016/j.acuroe.2014.05.003

Cited by 28 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bacteriuria was more frequently reported in patients receiving fosfomycin (8.6% versus 4.2%; P ϭ 0.02), but resistance was more frequently reported after ciprofloxacin treatment (41.9% versus 69.2%; P ϭ 0.0004). Both treatments were well tolerated (254).…”

Section: Prophylaxismentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

Section: Prophylaxismentioning

confidence: 99%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In our study, we administered 3 g of FT 3 h before the procedure, in line with the findings in the Rhodes's study [27]; moreover, in accordance with the national registration recommendations we also gave a second dose after the procedure. Recently, Lista et al [29] demonstrated, in a randomized prospective study on 671 patients who had undergone TR-PB, that antibiotic prophylaxis with FT (2 doses of 3 g) is a good alternative in terms of efficacy and safety when compared with a long-term therapy with CIP (10 doses of 500 mg). Moreover, the use of FT is correlated with lower rate of resistance [29].…”

mentioning

confidence: 99%

“…Recently, Lista et al [29] demonstrated, in a randomized prospective study on 671 patients who had undergone TR-PB, that antibiotic prophylaxis with FT (2 doses of 3 g) is a good alternative in terms of efficacy and safety when compared with a long-term therapy with CIP (10 doses of 500 mg). Moreover, the use of FT is correlated with lower rate of resistance [29]. In the Lista's study, the urine culture was carried out at 2 weeks after biopsy [29], while in our study we collected a urine culture at 30 days from the procedure.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative

Cai

Gallelli²,

Cocci

et al. 2016

World J Urol

View full text Add to dashboard Cite

infections (UTIs) occurring within 1 month after TR-PB. The rate of symptomatic UTIs and the rate of ADRs were considered the main outcome measures. Results In the total study population, 72/1109 (6.5 %) patients experienced symptomatic UTIs and among these 11 (0.9 % of total) had urosepsis. Out of 72, 53 (73.6 %) symptomatic UTIs were caused by fluoroquinolone-resistant strains. Out of 632, 10 (1.6 %) patients in Group 1 and 62/477 (12.9 %) patients in Group 2 had symptomatic UTIs (p < 0.001); in particular, 2/632 (0.3 %) patients in Group 1 and 9/477 (1.8 %) patients in Group 2 had urosepsis (p < 0.001). No differences were reported in terms of adverse events (0.6 vs 0.4 %; p = 0.70). A Charlson comorbidity index ≤1 and type of antimicrobial prophylaxis (FT) were found to be associated with a lower probability of symptomatic UTIs in the multivariate model. Conclusions Antibiotic prophylaxis with FT for TR-PB had a lower rate of adverse events and a lower rate of symptomatic UTIs as compared with CIP. Fosfomycin trometamol appears as an attractive alternative prophylactic regimen in prostate biopsies.

show abstract

“…To prevent infectious complications of TRUSBP, alternative prophylactic regimens, such as fosfomycin (single-or doubledose), were used. [6][7][8] Fosfomycin has a broad antibacterial spectrum of activity against the most common Gram-positive (Staphylococcus spp. and streptococci) and Gram-negative (Escherichia coli, Enterobacter spp., Klebsiella spp., Proteus spp., Citrobacter spp.)…”

Section: Introductionmentioning

confidence: 99%